Organoids Reveal How COVID-19 Damages Brain Cells
Synopsis: SARS-CoV-2 infections can result in long-lasting neurological symptoms; new research suggests an already approved anti-viral may inhibit viral replication and rescue impaired neurons. Long COVID, characterized by persisting symptoms that include neurological impairment, remains poorly understood and without any specific remedy. Though primarily considered to be a respiratory disease, COVID-19 can cause temporary or long-lasting neurological symptoms in some patients, ranging from loss of taste and smell, impaired concentration (brain fog), and psychological effects such as depression to stroke, epilepsy, and encephalopathy (a change in brain function or structure).
The term "Organoid" was coined in the Netherlands about ten years ago by Professor Hans Clevers, who was then an important researcher in stem cell research. Lancaster and Knoblich define an organoid as a collection of organ-specific cell types that develops from stem cells or organ progenitors, self-organizes through cell sorting and spatially restricted lineage commitment like in vivo, and exhibits the following properties:
- It has multiple organ-specific cell types.
- Its cells are grouped together and spatially organized, similar to an organ.
- It can recapitulate specific organ functions (e.g., contraction, neural activity, endocrine secretion, filtration, excretion).
The use of organoids has already found application in areas such as developmental biology, regenerative medicine, disease modeling, drug discovery, and personalized medicine.
Using human brain organoids, an international team of researchers, led by scientists at the University of California San Diego School of Medicine and Sanford Consortium, has shown how the SARS-CoV-2 virus that causes COVID-19 infects cortical neurons and specifically destroys their synapses - the connections between brain cells that allow them to communicate with each other.
The findings, published in the November 3, 2022 issue of PLOS Biology, also report that the antiviral drug sofosbuvir, already an approved treatment for hepatitis C, effectively inhibited SARS-CoV-2 replication and reversed neuronal alterations in infected brain organoids.
"Vaccines and emerging treatments have reduced the health consequences of COVID-19 in most patients," said senior study author Alysson R. Muotri, Ph.D., professor in departments of Pediatrics and Cellular and Molecular at UC San Diego School of Medicine. "But the phenomenon of Long COVID, characterized by persisting symptoms that include neurological impairment, remains poorly understood and without any specific remedy."
"This work helps explain some of the neurological symptoms of COVID-19 and, more importantly, it suggests that an FDA-approved antiviral drug might be repurposed to restore infected brain cells to health and address long-term neurological outcomes of COVID-19."
Though primarily considered to be a respiratory disease, COVID-19 can cause temporary or long-lasting neurological symptoms in some patients, ranging from loss of taste and smell, impaired concentration (brain fog), and psychological effects such as depression to stroke, epilepsy, and encephalopathy (a change in brain function or structure).
With evidence accumulating that the SARS-CoV-2 virus can infect and alter brain cells (including in developing fetuses), the research team focused on using organoids - self-organizing, three-dimensional tissues derived from cultured stem cells that can mimic some organ functions.
Researchers exposed the brain organoids to SARS-CoV-2, observed viral infection and replication, and noted that the virus rapidly decreased the number of excitatory synapses in neurons within seven days post-infection. Excitatory synapses increase the firing action potential of a neuron, while their counterparts, called inhibitory synapses, decrease that potential.
However, when infected organoids were treated with sofosbuvir, viral replication was inhibited, and neurological impairments were observed or restored. The findings echo earlier computational models that suggested sofosbuvir could be a treatment and previous research by Muotri and colleagues that found sofosbuvir effectively protected and rescued neural cells infected by the Zika virus.
"The bottom line is that sofosbuvir appears to have the potential to arrest or prevent the development of neurological symptoms in COVID-19 patients," Muotri said. "And because it has been shown to present no safety concerns in pregnant women, it might also be an option for preventing SARS-CoV-2 transmission to their unborn children."
"Further studies and clinical trials are needed, of course, but these findings offer a path forward for treating a condition (Long COVID) that has so far stymied remedy for millions of people worldwide."
Pinar Mesci, Janaina S. de Souza, Angela Macia, Aurian Saleh, Cedric Snethlage, Jason W. Adams, Angels Almenar-Queralt, Ryan A. Szeto, Gabriela Goldberg, and Patrick T. Bruck, all at UC San Diego and Rady Children's Hospital-San Diego.
Laura Martin-Sancho, Yuan Pu and Sumit K. Chandra, Sanford Burnham Prebys Medical Discovery Institute.
Simoni H. Avansini and Fabio Papes, UC San Diego and University of Campinas, Brazil.
Roberto H. Herai, Pontificia Universidade Catolica do Parana, Brazil and Lico Kaesemodel Institute, Brazil.
This peer reviewed publication pertaining to our Organoids section was selected for circulation by the editors of Disabled World due to its likely interest to our disability community readers. Though the content may have been edited for style, clarity, or length, the article "Organoids Reveal How COVID-19 Damages Brain Cells" was originally written by University of California - San Diego, and submitted for publishing on 2022/11/06 (Edit Update: 2023/01/03). Should you require further information or clarification, University of California - San Diego can be contacted at the ucsd.edu website. Disabled World makes no warranties or representations in connection therewith.
📢 Discover Related Topics
👍 Share This Information To:
𝕏.com Facebook Reddit
Page Information, Citing and Disclaimer
Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.
Permalink: <a href="https://www.disabled-world.com/news/research/organoids/covid-brain.php">Organoids Reveal How COVID-19 Damages Brain Cells</a>
Cite This Page (APA): University of California - San Diego. (2022, November 6). Organoids Reveal How COVID-19 Damages Brain Cells. Disabled World. Retrieved February 24, 2024 from www.disabled-world.com/news/research/organoids/covid-brain.php
Disabled World provides general information only. Materials presented are never meant to substitute for qualified professional medical care. Any 3rd party offering or advertising does not constitute an endorsement.